These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 21275455

  • 1. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
    Shiroiwa T, Motoo Y, Tsutani K.
    Mol Diagn Ther; 2010 Dec 01; 14(6):375-84. PubMed ID: 21275455
    [Abstract] [Full Text] [Related]

  • 2. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1182-92. PubMed ID: 19666851
    [Abstract] [Full Text] [Related]

  • 3. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.
    J Med Econ; 2013 Dec 02; 16(12):1387-98. PubMed ID: 24102083
    [Abstract] [Full Text] [Related]

  • 4. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M.
    Clin Cancer Res; 2011 Oct 01; 17(19):6338-46. PubMed ID: 21807639
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.
    Value Health; 2013 Oct 01; 16(2):288-96. PubMed ID: 23538180
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM.
    Int J Cancer; 2012 Jul 15; 131(2):438-45. PubMed ID: 21898389
    [Abstract] [Full Text] [Related]

  • 7. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
    Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.
    Health Technol Assess; 2014 Oct 15; 18(62):1-132. PubMed ID: 25314637
    [Abstract] [Full Text] [Related]

  • 8. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C.
    Health Technol Assess; 2013 Apr 15; 17(14):1-237. PubMed ID: 23547747
    [Abstract] [Full Text] [Related]

  • 9. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
    Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG.
    Clin Ther; 2016 Jun 15; 38(6):1376-1391. PubMed ID: 27085587
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
    Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV.
    J Natl Cancer Inst; 2012 Dec 05; 104(23):1785-95. PubMed ID: 23197490
    [Abstract] [Full Text] [Related]

  • 11. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.
    Barone C, Pinto C, Normanno N, Capussotti L, Cognetti F, Falcone A, Mantovani L.
    PLoS One; 2014 Dec 05; 9(1):e85897. PubMed ID: 24465771
    [Abstract] [Full Text] [Related]

  • 12. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P, Jones R, Paisley S, Carroll C.
    Health Technol Assess; 2007 Mar 05; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [Abstract] [Full Text] [Related]

  • 13. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
    Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ.
    J Clin Oncol; 2009 Apr 10; 27(11):1822-8. PubMed ID: 19273701
    [Abstract] [Full Text] [Related]

  • 14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 10; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 15. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.
    JAMA; 2010 Oct 27; 304(16):1812-20. PubMed ID: 20978259
    [Abstract] [Full Text] [Related]

  • 16. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
    Frank M, Mittendorf T.
    Pharmacoeconomics; 2013 Mar 27; 31(3):215-28. PubMed ID: 23338963
    [Abstract] [Full Text] [Related]

  • 17. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
    Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G.
    Clin Ther; 2012 Oct 27; 34(10):2132-42. PubMed ID: 23063374
    [Abstract] [Full Text] [Related]

  • 18. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
    Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Iv GA.
    Arch Pathol Lab Med; 2013 Jun 27; 137(6):820-7. PubMed ID: 23030695
    [Abstract] [Full Text] [Related]

  • 19. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.
    Cancer; 2013 Feb 15; 119(4):714-21. PubMed ID: 22972628
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.